{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:21:41Z","timestamp":1769520101856,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.leukres.2019.01.005","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T11:29:24Z","timestamp":1547638164000},"page":"24-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A registry-based analysis of survival outcomes in mast cell leukemia"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3543-0305","authenticated-orcid":false,"given":"Justin","family":"Budnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.leukres.2019.01.005_bib0005","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"127","key":"10.1016\/j.leukres.2019.01.005_bib0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2019.01.005_bib0015","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2019.01.005_bib0020","first-page":"437","article-title":"Uber mastzellenleukamien","volume":"87","author":"Joachim","year":"1906","journal-title":"Deutsches Archives fur Klinische Medizin"},{"key":"10.1016\/j.leukres.2019.01.005_bib0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.leukres.2017.05.018","article-title":"Mast cell leukemia (MCL): clinico-pathologic and molecular features and survival outcome","volume":"59","author":"Jain","year":"2017","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.leukres.2019.01.005_bib0030","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2019.01.005_bib0035","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3324\/haematol.2017.163964","article-title":"The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm","volume":"102","author":"Jawhar","year":"2017","journal-title":"Haematologica."},{"key":"10.1016\/j.leukres.2019.01.005_bib0040","series-title":"First Revision","article-title":"International classification of diseases for oncology","year":"2013"},{"issue":"1","key":"10.1016\/j.leukres.2019.01.005_bib0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika."},{"key":"10.1016\/j.leukres.2019.01.005_bib0050","series-title":"Stata Statistical Software: Release 14. College Station, TX: StataCorp LP","author":"StataCorp","year":"2015"},{"issue":"5","key":"10.1016\/j.leukres.2019.01.005_bib0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.leukres.2019.01.005_bib0060","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gcc.22526","article-title":"Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis","volume":"57","author":"Naumann","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"26","key":"10.1016\/j.leukres.2019.01.005_bib0065","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2019.01.005_bib0070","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2019.01.005_bib0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2019.01.005_bib0080","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-0609.2011.01598.x","article-title":"A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib","volume":"86","author":"Mital","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2019.01.005_bib0085","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.V124.21.636.636","article-title":"Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial","volume":"124","author":"Gotlib","year":"2014","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2019.01.005_bib0090","first-page":"S207","article-title":"Successful treatment of systemic mastocytosis associated with AML-M2, t (8: 21) in a child using MRC-based AML chemotherapy along with gemtuzumab","volume":"119","author":"Jeong","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.leukres.2019.01.005_bib0095","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/leu.2016.30","article-title":"Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia","volume":"30","author":"Alvarez-Twose","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.01.005_bib0100","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2019.01.005_bib0105","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00277-007-0430-3","article-title":"Mast cell leukemia: a report of ten cases","volume":"87","author":"Valentini","year":"2008","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2019.01.005_bib0110","first-page":"621","article-title":"Acute mast cell leukemia disclosed by vasomotor flushing","volume":"124","author":"Le Cam","year":"1997","journal-title":"Ann. Dermatol. Venereol."},{"issue":"5","key":"10.1016\/j.leukres.2019.01.005_bib0115","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1525-1470.2011.01650.x","article-title":"Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia","volume":"29","author":"Chantorn","year":"2012","journal-title":"Pediatr. Dermatol."},{"issue":"4","key":"10.1016\/j.leukres.2019.01.005_bib0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","article-title":"A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis","volume":"37","author":"Nakamura","year":"2006","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.leukres.2019.01.005_bib0125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.bmt.1704098","article-title":"Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation","volume":"32","author":"Chen","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2019.01.005_bib0130","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.01.005_bib0135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/10428199609054789","article-title":"Treatment of three patients with systemic mastocytosis with interferon alpha-2b","volume":"22","author":"Worobec","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2019.01.005_bib0140","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2019.01.005_bib0145","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk. Res."},{"issue":"22","key":"10.1016\/j.leukres.2019.01.005_bib0150","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2169\/internalmedicine.48.2294","article-title":"Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha","volume":"48","author":"Yoshida","year":"2009","journal-title":"Intern. Med."},{"issue":"3","key":"10.1016\/j.leukres.2019.01.005_bib0155","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/1042819021000046976","article-title":"Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs","volume":"44","author":"Samorapoompichit","year":"2003","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.leukres.2019.01.005_bib0160","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/jcp.2006.040857","article-title":"Mast-cell sarcoma of the tibia","volume":"60","author":"Brcic","year":"2007","journal-title":"J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.leukres.2019.01.005_bib0165","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1053\/apmr.2002.32308","article-title":"Low back pain and myalgias in acute and relapsed mast cell leukemia: a case report","volume":"83","author":"Lin","year":"2002","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.leukres.2019.01.005_bib0170","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.01.005_bib0175","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.01.005_bib0180","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.exphem.2010.05.006","article-title":"In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V","volume":"38","author":"B\u00f6hm","year":"2010","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2019.01.005_bib0185","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2019.01.005_bib0190","article-title":"Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies","volume":"109","author":"Xao","year":"2017","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T09:59:00Z","timestamp":1573725540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619300050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":38,"alternative-id":["S0145212619300050"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.01.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A registry-based analysis of survival outcomes in mast cell leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}